crohn's and semaglutide Disease: Safety, Risks, and What Patients Should Know GLP-1s and Crohn's Disease: Safety,
Description
BMI Criteria, Costs & Eligibility Explained (2026)
Potential risks include GI issues, glucose changes, joint pain, hormone imbalance, and more
Maybe youre sipping your morning coffee, and a familiar train of thought pulls in: Whats for lunch
Hypoglycaemia risk is generally low with GLP-1 agonists when used as monotherapy, as their glucose-lowering effect is glucose-dependent
Their higherdose counterparts, Wegovy (semaglutide) and Zepbound (tirzepatide), are the versions that are specifically FDAapproved for chronic weight management in people with obesity or overweight plus a weightrelated condition
Strut Health uses a secure health portal and a broader telehealth setup
